Lyell Immunopharma, Inc. announced that Matthew Lang, J.D. has joined the executive management team as Chief Business Officer. In this newly created role, Mr. Lang will serve on Lyell’s executive committee and will be responsible for Lyell’s legal, compliance, human resources, alliance management and early commercialization teams. He will also serve as Lyell’s Chief Legal Officer and Corporate Secretary. Mr. Lang was previously Chief Administrative and Legal Officer and Corporate Secretary at Myovant Sciences where he built and led numerous functions at various stages including legal, compliance, human resources, alliance management, corporate communications, and risk management and helped build and lead the company through Phase 3 clinical development and global approval and commercialization of Myfembree® and Orgovyx®.

While at Myovant, he negotiated numerous US and European co-development, licensing and commercialization deals as well as multiple financing and acquisition transactions totaling over $7.5 billion. Mr. Lang also served as the Managing Director and General Manager of Myovant’s European operations in Basel Switzerland where he was responsible for all aspects of Myovant’s ex-US business operations. Prior to Myovant, Mr. Lang held positions as Vice President, Head of Global Litigation, Investigations, Employment Law and Information Governance at Gilead Sciences, Inc. At Gilead, in addition to leading core functions within the legal department, Mr. Lang was a member of the company's corporate operating group, global legal leadership team, and global compliance committee.

Prior to Gilead, Mr. Lang was an attorney at Dechert LLP in New York City. Mr. Lang received his BA in Classical Studies from Queen's University at Kingston in Canada and his J.D. from the University of Pennsylvania Law School.